CRBP
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ · USHealthcareBiotechnology
$8.89-1.33%
Price as of Jul 20, 2026
CRBP financials
Corbus Pharmaceuticals Holdings, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $0.00 | $600.0K | $0.00 | $1.5M |
| Gross profit | $0.00 | -$600.0K | $0.00 | -$1.5M |
| Operating expenses | $85.3M | $48.1M | $45.1M | $33.3M |
| Operating income | -$85.3M | -$48.7M | -$45.1M | -$34.8M |
| Net income | -$78.5M | -$40.2M | -$44.6M | -$55.8M |
| EBITDA | -$78.3M | -$37.7M | -$40.1M | -$38.7M |
| Basic EPS | $-5.90 | $-3.68 | $-10.31 | $-10.15 |
| Diluted EPS | $-5.90 | $-3.68 | $-10.31 | $-10.15 |
| Balance sheet | ||||
| Cash & equivalents | $28.5M | $17.2M | $13.7M | $17.0M |
| Total assets | $168.2M | $155.9M | $28.3M | $66.3M |
| Total liabilities | $20.7M | $13.5M | $35.2M | $33.3M |
| Stockholders’ equity | $147.5M | $142.4M | -$6.9M | $33.0M |
| Total debt | $1.6M | $3.2M | $20.9M | $25.1M |
| Net debt | -$26.9M | -$14.0M | $7.2M | $8.1M |
| Cash flow | ||||
| Operating cash flow | -$64.5M | -$41.8M | -$36.1M | -$37.5M |
| Capital expenditure | -$7.0K | $0.00 | $3.00 | -$13.4K |
| Free cash flow | -$64.5M | -$41.8M | -$36.1M | -$37.6M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |